| Literature DB >> 24283971 |
Lili M Portilla, Mark L Rohrbaugh1.
Abstract
The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.Entities:
Mesh:
Year: 2014 PMID: 24283971 PMCID: PMC4023345 DOI: 10.2174/1568026613666131127155703
Source DB: PubMed Journal: Curr Top Med Chem ISSN: 1568-0266 Impact factor: 3.295